Patents by Inventor Mark Richard Fielding

Mark Richard Fielding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for Making a Metabotropic Glutamate Receptor Positive Allosteric Modulator - 874
    Publication number: 20130203995
    Abstract: Processes for making 7-methyl-5-(3piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one
    Type: Application
    Filed: January 4, 2011
    Publication date: August 8, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Alistair Boyd, Mark Richard Fielding, James Gair Ford, Lianne Frodsham, Michael D. Golden, Kevin William Leslie, Ben Mckeever-Abbas, Paula Tomlin
  • Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
    Patent number: 8299076
    Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: October 30, 2012
    Assignees: Array Biopharma Inc., Astrazeneca AB
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, Jim Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226
    Publication number: 20110015392
    Abstract: A route for preparing a compound of formula (I) where X, R1, R2, R7, R8 and R9 are as defined in the specification, is described. Process steps used in the route and novel intermediates prepared during the route are also described and claimed. Compounds of formula (I) are used in the preparation of pharmaceutical compounds, in particular inhibitors of MEK, useful in the treatment of hyperproliferative disease such as cancer and inflammatory conditions.
    Type: Application
    Filed: August 11, 2010
    Publication date: January 20, 2011
    Inventors: Mark Richard Fielding, John Leonard
  • Heterocyclic Inhibitors of Mek and Methods of Use Thereof
    Publication number: 20080280957
    Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: May 17, 2006
    Publication date: November 13, 2008
    Applicants: ARRAY BIOPHARMA, INC., ASTRAZENECA AB
    Inventors: Allison L. Marlow, Eli M. Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hoog Woon Yang, James Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding